Tigermed | Briefing, News, Analysis, Research, Data

Tigermed

Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.

Tigermed, founded in December, 2014 and headquartered in Hangzhou, is a contract research organization (CRO) focused on providing professional services for the entire process of clinical trials for new drug research. The founder is Ye Xiaoping. Listed on the SZSE on August 17, 2012, the company's major shareholders are Ye Xiaoping, Hong Kong Securities Clearing Co., Ltd and Cao Xiaochun. Rivals that have direct and indirect competition with Tigermed include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Generic Pharma

Founded

Dec 1, 2014

HQ location

Zhejiang, China

Legal name

Hangzhou Tigermed Consulting Co., Ltd.

Website

http://www.tigermed.net

ir@tigermed.net

Employees

1001-5000

All
News
Analysis
Research

Briefing Jun 24, 2022 10:39 AM · Technology | Healthcare | Industrials

The maximum payment limit of employee medical insurance in Shanghai in 2022 was raised to 590000 yuan

Briefing Jun 13, 2022 10:14 AM · Technology | Consumer Staples | Communication

The private placement market is full of chaos, and the regulators' sword is intended to support the good and limit the bad

In-depth

Three-dimensional landscape of genome. Image credit: National Cancer Institute/Unsplash

Healthcare

Clinical CRO Tigermed: The ‘Small and Beautiful’

In this race of pharmaceutical R&D outsourcing segment, WuXi AppTec, Pharmaron, Tigermed and Asychem are some of the major names – but which has a truly winning side?

Jun 14, 2020 11:00 AM

Briefing Jun 13, 2022 09:44 AM · Healthcare

Cro plate fell, and Wuxi apptec fell nearly 10%

Briefing Apr 26, 2022 05:05 PM · Technology | Consumer Discretionary | Healthcare

Tiger medicine: net profit in the first quarter increased by 13.82% year-on-year

Research

Healthcare

Digital Therapeutics - Revolution of the healthcare system

Nov 16, 2022 05:19 PM

Research

Healthcare

2022 China AI Health 30 Report

Nov 07, 2022 04:27 PM

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Consumer Staples, Healthcare, Technology

WIA2020 | Rising Tech Stars 2020: Global & China's 100

Dec 09, 2020 09:57 AM

Briefing Apr 19, 2022 11:34 AM · Consumer Staples | Healthcare | Financials

The steel plate rose and Jinling mining rose by the limit

Briefing Mar 10, 2022 07:38 PM · Technology | Healthcare | Financials

The leaders of Russia, France and Germany talked on the phone to discuss the situation in Ukraine

Briefing Feb 21, 2022 10:29 AM · Healthcare

Baidu responded that it was unable to search "referee document network": caused by misoperation of the technical team

Briefing Feb 15, 2022 05:21 PM · Technology | Consumer Staples | Healthcare

All Nippon Airways will cooperate with Joby, an enterprise invested by Toyota, on the flying car business, which is planned to be practical in 2025

Healthcare

Reforgene Completes Pre-B Round Financing of CNY Hundreds of Millions

EqualOcean learned that Reforgene Medicine (瑞风生物) recently announced the completion of Pre-B round financing of CNY hundreds of millions.

May 04, 2023 02:05 PM

Healthcare

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

Jul 05, 2022 08:17 PM

Briefing Feb 10, 2022 10:19 AM · Technology | Consumer Staples | Healthcare

Baby concept stock change

Briefing Jan 26, 2022 04:29 PM · Technology | Consumer Staples | Healthcare

Kuangda Technology: sign a 5.5 billion yuan filter chip R & D and production project

Briefing Jan 26, 2022 01:19 PM · Consumer Staples | Healthcare | Automotive

Kia's fourth quarter sales were 17.19 trillion won, lower than expected

The biotech lab tests are in great demand. Image credit_thisisengineering/Unsplash

Healthcare

CRO Giant Tigermed’s 1H 2020 Net Profits Up 98%

Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.

Aug 29, 2020 09:02 PM

In-depth

The research lab is the core engine in pharmaceutical. Image credit: Hans Reniers/Unsplash

Healthcare

WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell

According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index. It has been considered a top holding by many MSCI China indexes for some time.

Jun 08, 2020 09:51 AM

Briefing Dec 29, 2021 09:39 AM · Consumer Staples | Healthcare

The pharmaceutical and biological sector has been heavily sold off by the main funds in the past three days

Briefing Dec 13, 2021 01:40 PM · Consumer Staples | Communication | Healthcare

"Lingjing oasis" completed ten million yuan financing

Briefing Nov 01, 2021 09:08 PM · Technology | Healthcare | Automotive

Tiger medicine: after the share repurchase, the total transaction amount is about 500 million yuan

Briefing Oct 19, 2021 10:11 AM · Healthcare

Cro stocks rose in early trading

EqualOcean Analysis